TaiGen Biopharmaceuticals Holdings (ROCO:4157) Research & Development: NT$96.9 Mil (TTM As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ROCO:4157 TaiGen Biopharmaceuticals Holdings Ltd ROCO:4157
59 GF Score
Price NT$8.90
GF Value NT$34.16
Valuation Significantly Undervalued
View Full Analysis

What is TaiGen Biopharmaceuticals Holdings Research & Development?

TaiGen Biopharmaceuticals Holdings ROCO:4157 +0.34% 59 Research & Development is NT$96.9 Mil as of Dec. 2025. GuruFocus rates ROCO:4157 with a GF Score™ of 59/100 and a GF Value™ of NT$34.16 (Significantly Undervalued).

Research & Development is the aggregate amount of research and development expenses during the year. TaiGen Biopharmaceuticals Holdings's Research & Development for the three months ended in Dec. 2025 was NT$22.4 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Dec. 2025 was NT$96.9 Mil.

TaiGen Biopharmaceuticals Holdings  (ROCO:4157) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

TaiGen Biopharmaceuticals Holdings Research & Development Related Terms

TaiGen Biopharmaceuticals Holdings Research & Development Historical Data

* Premium members only.

The historical data trend for TaiGen Biopharmaceuticals Holdings's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

TaiGen Biopharmaceuticals Holdings Research & Development Chart

TaiGen Biopharmaceuticals Holdings Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 283.28 237.52 187.48 166.07 96.88

TaiGen Biopharmaceuticals Holdings Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 42.43 28.81 23.72 21.98 22.37
ROCO:4157
59GF Score
TaiGen Biopharmaceuticals Holdings Ltd ROCO:4157
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

TaiGen Biopharmaceuticals Holdings Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$96.9 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of NT$96.9 Mil mean?
TaiGen Biopharmaceuticals Holdings (ROCO:4157) has a Research & Development of NT$96.9 Mil as of Dec. 2025. Research and development expense is the total cost for research and development activities. View historical data on TaiGen Biopharmaceuticals Holdings and its competitors.
Is TaiGen Biopharmaceuticals Holdings' Research & Development too high?
TaiGen Biopharmaceuticals Holdings' current Research & Development is NT$96.9 Mil. Overall, TaiGen Biopharmaceuticals Holdings has a GF Score™ of 59/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does TaiGen Biopharmaceuticals Holdings' Research & Development compare to VRTX and REGN?
TaiGen Biopharmaceuticals Holdings' Research & Development of NT$96.9 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Biotechnology company?
A good Research & Development depends on the Biotechnology industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on TaiGen Biopharmaceuticals Holdings and its competitors. TaiGen Biopharmaceuticals Holdings's current Research & Development is NT$96.9 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is TaiGen Biopharmaceuticals Holdings stock overvalued right now?
Based on GuruFocus' analysis, TaiGen Biopharmaceuticals Holdings (ROCO:4157) is currently considered Significantly Undervalued. The stock's GF Value™ is NT$34.16, compared to a current price of NT$8.90 — trading 73.9% below its estimated fair value. The current Research & Development is NT$96.9 Mil. TaiGen Biopharmaceuticals Holdings' overall GF Score™ is 59/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For TaiGen Biopharmaceuticals Holdings (ROCO:4157), the current Research & Development is NT$96.9 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is TaiGen Biopharmaceuticals Holdings (ROCO:4157) Overvalued in 2026?

Based on GuruFocus' analysis, TaiGen Biopharmaceuticals Holdings stock appears to be undervalued. The current stock price of NT$8.90 is trading 73.9% below its estimated GF Value™ of NT$34.16. GuruFocus considers TaiGen Biopharmaceuticals Holdings to be Significantly Undervalued.

Key valuation signals for ROCO:4157:

  • Research & Development: NT$96.9 Mil
  • GF Value™: NT$34.16 vs. price of NT$8.90 (73.9% below fair value)
  • GF Score™: 59/100

No single metric tells the full story. See the ROCO:4157 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

TaiGen Biopharmaceuticals Holdings Business Description

Address No. 138 Xinming Road, 7th Floor, Neihu District, Taipei, TWN, 114
TaiGen Biopharmaceuticals Holdings Ltd is mainly engaged in the research and development of new drugs, including the selection of drug candidates, pre-IND trials and clinical trials. Its operating segment includes development, research and sales of new drugs, and other. The majority of the revenue is generated from development, research and sales of new drugs.
59GF Score

Get the complete analysis for ROCO:4157

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$8.90
Price
NT$34.16
GF Value